In comparison with other DNL-inhibiting agents subject to clinical investigations in NAFLD, ACC inhibitors apparently show superior efficacy in reducing liver fat content and ALT. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.